melatonin in treatment of climacteric symptoms

Clicks: 119
ID: 151180
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #17 of 27 articles by views in journal of sports medicine and physical fitness

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
During menopausal transition women develop vasomotor and psychosomatic symptoms. These symptoms stem both from estrogen deprivation and hypothalamic-pituitary system ageing. Melatonin is a powerful hormonal adaptogen, working at every level of reproductive system, down to receptor level. To measure its effect on climacteric symptoms, we enrolled 55 women between 45 and 65 y.o. All participants took 3 mg of melatonin - Melaxen (Unipharm, Inc.) for 3 months. During the therapy we observed marked reduction of symptoms from 40.96 to 21.36 (47.92%) on Greene Climacteric Scale and sleep improvement from 16.60±4.03 to 7.33±1.95 on Pittsburgh Sleep Quality Index. Melatonin 3 mg is an effective method of climacteric symptoms therapy.
Reference Key
kuznetsova2015melatonin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;I V Kuznetsova;D I Burchakov
Journal journal of sports medicine and physical fitness
Year 2015
DOI
DOI not found
URL
https://gynecology.orscience.ru/2079-5831/article/viewFile/28481/pdf
Keywords
treatment menopausal symptoms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.